ES2915473T3 - Dominios variables únicos de inmunoglobulina para su uso en métodos de tratamiento de TTP - Google Patents

Dominios variables únicos de inmunoglobulina para su uso en métodos de tratamiento de TTP Download PDF

Info

Publication number
ES2915473T3
ES2915473T3 ES18153673T ES18153673T ES2915473T3 ES 2915473 T3 ES2915473 T3 ES 2915473T3 ES 18153673 T ES18153673 T ES 18153673T ES 18153673 T ES18153673 T ES 18153673T ES 2915473 T3 ES2915473 T3 ES 2915473T3
Authority
ES
Spain
Prior art keywords
polypeptide
vwf
human
hrs
ttp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18153673T
Other languages
English (en)
Spanish (es)
Inventor
Christian Duby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Application granted granted Critical
Publication of ES2915473T3 publication Critical patent/ES2915473T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES18153673T 2014-06-16 2015-06-16 Dominios variables únicos de inmunoglobulina para su uso en métodos de tratamiento de TTP Active ES2915473T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2013007A NL2013007B1 (en) 2014-06-16 2014-06-16 Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
US201462030817P 2014-07-30 2014-07-30

Publications (1)

Publication Number Publication Date
ES2915473T3 true ES2915473T3 (es) 2022-06-22

Family

ID=51541255

Family Applications (5)

Application Number Title Priority Date Filing Date
ES18153673T Active ES2915473T3 (es) 2014-06-16 2015-06-16 Dominios variables únicos de inmunoglobulina para su uso en métodos de tratamiento de TTP
ES18153674T Active ES2924199T3 (es) 2014-06-16 2015-06-16 Dominios variables individuales de inmunoglobulina para el uso en métodos para tratar TTP
ES18153671T Active ES2843642T3 (es) 2014-06-16 2015-06-16 Métodos de tratamiento de TTP con dominios variables únicos de inmunoglobulina y usos de los mismos
ES15729829T Active ES2881331T3 (es) 2014-06-16 2015-06-16 Dominios variables únicos de inmunoglobulina para su uso en el tratamiento de TTP
ES18153676T Active ES2831865T3 (es) 2014-06-16 2015-06-16 Dominios variables únicos de inmunoglobulina para su uso en métodos de tratamiento de TTP

Family Applications After (4)

Application Number Title Priority Date Filing Date
ES18153674T Active ES2924199T3 (es) 2014-06-16 2015-06-16 Dominios variables individuales de inmunoglobulina para el uso en métodos para tratar TTP
ES18153671T Active ES2843642T3 (es) 2014-06-16 2015-06-16 Métodos de tratamiento de TTP con dominios variables únicos de inmunoglobulina y usos de los mismos
ES15729829T Active ES2881331T3 (es) 2014-06-16 2015-06-16 Dominios variables únicos de inmunoglobulina para su uso en el tratamiento de TTP
ES18153676T Active ES2831865T3 (es) 2014-06-16 2015-06-16 Dominios variables únicos de inmunoglobulina para su uso en métodos de tratamiento de TTP

Country Status (15)

Country Link
US (5) US10858445B2 (enExample)
EP (6) EP3366305B1 (enExample)
JP (3) JP6688746B2 (enExample)
KR (2) KR102403388B1 (enExample)
CN (1) CN106559985A (enExample)
AU (2) AU2015276237B2 (enExample)
CA (1) CA2952103A1 (enExample)
ES (5) ES2915473T3 (enExample)
IL (1) IL249540B (enExample)
NL (1) NL2013007B1 (enExample)
PL (5) PL3335724T3 (enExample)
PT (5) PT3335724T (enExample)
RU (1) RU2704444C2 (enExample)
SG (2) SG10201811109PA (enExample)
WO (1) WO2015193326A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN107340225B (zh) * 2017-07-13 2019-07-05 徐州医科大学 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
MY204220A (en) * 2018-02-06 2024-08-16 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
MX2023005661A (es) * 2020-11-18 2023-05-26 Green Cross Corp Variante de adamts13 que tiene actividad o velocidad de escape incrementada contra un autoanticuerpo.
AU2022345251A1 (en) 2021-09-17 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
CN118715246A (zh) * 2021-12-10 2024-09-27 李人浩 结合血管性血友病因子(vwf)a1结构域或自动抑制模块的多肽、变体及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
JP2002535993A (ja) 1999-02-05 2002-10-29 リイクスニフェルシタイト ライデン 組換え体細胞における代謝物の生合成を変調する方法
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
EP1565482B1 (en) 2002-10-23 2014-04-30 Ludwig Institute for Cancer Research Ltd. A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
RU2524129C2 (ru) 2003-01-10 2014-07-27 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
JP2007521234A (ja) 2003-08-12 2007-08-02 ウィリアム エム ヤーブロー 尋常性ざ瘡の治療薬及び使用方法
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
PL1836500T3 (pl) 2005-01-14 2010-12-31 Ablynx Nv Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi
DK2444424T3 (en) * 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
AU2008252853B2 (en) 2007-05-24 2011-12-01 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2252303A2 (en) 2008-03-21 2010-11-24 Ablynx NV Von willebrand factor specific binders and methods of use therefor
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
EP2506874A1 (en) 2009-12-01 2012-10-10 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
BR112013011176A2 (pt) * 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
SI2717905T1 (sl) 2011-06-10 2018-09-28 Baxalta GmbH Obravnava bolezni koagulacije z dajanjem rekombinantnega vwf
PH12014500380A1 (en) 2011-08-17 2022-05-02 Glaxo Group Ltd Modified proteins and peptides
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
MY204220A (en) 2018-02-06 2024-08-16 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains

Also Published As

Publication number Publication date
EP3335723A1 (en) 2018-06-20
ES2831865T3 (es) 2021-06-09
EP3335724A1 (en) 2018-06-20
JP6688746B2 (ja) 2020-04-28
ES2843642T3 (es) 2021-07-19
PL3332800T3 (pl) 2021-04-19
KR102568585B1 (ko) 2023-08-18
AU2015276237A1 (en) 2017-01-19
EP3154569B1 (en) 2021-04-21
ES2881331T3 (es) 2021-11-29
RU2017100077A3 (enExample) 2018-12-25
KR20220053040A (ko) 2022-04-28
KR102403388B1 (ko) 2022-06-03
WO2015193326A1 (en) 2015-12-23
US10919980B2 (en) 2021-02-16
RU2019131713A (ru) 2019-11-11
SG11201610488QA (en) 2017-01-27
PT3332800T (pt) 2020-11-19
JP2020097600A (ja) 2020-06-25
PL3335723T3 (pl) 2022-07-18
EP3335724B1 (en) 2022-06-22
AU2015276237B2 (en) 2021-02-25
EP4059513A1 (en) 2022-09-21
US12269893B2 (en) 2025-04-08
EP3335723B1 (en) 2022-03-30
PT3335723T (pt) 2022-05-20
PT3366305T (pt) 2020-12-21
IL249540A0 (en) 2017-02-28
EP3332800A1 (en) 2018-06-13
RU2017100077A (ru) 2018-07-12
US20180155440A1 (en) 2018-06-07
PT3335724T (pt) 2022-08-02
PL3335724T3 (pl) 2022-09-19
HK1256730A1 (en) 2019-10-04
US20180155441A1 (en) 2018-06-07
CA2952103A1 (en) 2015-12-23
HK1258508A1 (en) 2019-11-15
PT3154569T (pt) 2021-06-22
AU2021202747B2 (en) 2024-02-15
US20170210822A1 (en) 2017-07-27
EP3332800B1 (en) 2020-08-26
US10858445B2 (en) 2020-12-08
AU2021202747A1 (en) 2021-05-27
JP7105260B2 (ja) 2022-07-22
NL2013007B1 (en) 2016-07-05
US20180155443A1 (en) 2018-06-07
SG10201811109PA (en) 2019-01-30
CN106559985A (zh) 2017-04-05
US20180155442A1 (en) 2018-06-07
EP3366305A1 (en) 2018-08-29
EP3366305B1 (en) 2020-11-18
RU2704444C2 (ru) 2019-10-28
JP2022160431A (ja) 2022-10-19
EP3154569A1 (en) 2017-04-19
JP2017519762A (ja) 2017-07-20
IL249540B (en) 2021-09-30
PL3366305T3 (pl) 2021-06-14
KR20170015513A (ko) 2017-02-08
PL3154569T3 (pl) 2021-11-02
ES2924199T3 (es) 2022-10-05
HK1256731A1 (en) 2019-10-04

Similar Documents

Publication Publication Date Title
ES2915473T3 (es) Dominios variables únicos de inmunoglobulina para su uso en métodos de tratamiento de TTP
TWI889647B (zh) 以免疫球蛋白單一可變域治療ttp初次發作之方法
HK40078326A (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof
RU2807602C2 (ru) Способы лечения ттп иммуноглобулиновыми одиночными вариабельными доменами и их применение
HK1256730B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1258508B (en) Methods of treating ttp with immunoglobulin single variable domains and uses thereof
HK1255930B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1255930A1 (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1256731B (en) Immunoglobulin single variable domains for use in methods of treating ttp
HK1236434B (en) Immunoglobulin single variable domains for use in treating ttp